Kastelein Johannes Jacob Pieter
Affiliate at NAMS
- Sold, on record
- $20.8M
- Dollars the filings state
- Form 4 sales
- 6
- Latest Aug 24, 2026
- Form 144 notices
- 6
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- NAMSNewAmsterdam Pharma Co N.V.Affiliate
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 144 notice NAMSNoticeJan 5, 2026 2026
Filed to sell 6,000 shares ($199k)
Kastelein Johannes Jacob Pieter, Affiliate
No 10b5-1 planFiling
- 2 Form 4 sale NAMSRoutineJan 5, 2026 same day
Sold 6,000 shares at $33.25 ($200k)
Kastelein Johannes Jacob Pieter, Chief Scientific Officer
10b5-1 planSold 7.5% of holdings ($2.6M position)73,481 shares leftFollows a Form 144Filing
- 3 Form 144 notice NAMSNoticeFeb 20, 2026 +46 days
Filed to sell 45,481 shares ($1.6M)
Kastelein Johannes Jacob Pieter, Officer, Director
No 10b5-1 plan0.5x usual sizeFiling
- 4 Form 4 sale NAMSUnusualFeb 20, 2026 same day
Sold 45,481 shares at $35.31 ($1.6M)
Kastelein Johannes Jacob Pieter, Chief Scientific Officer
No 10b5-1 planSold 45.9% of holdings ($3.5M position)53,500 shares left0.5x usual sizeFollows a Form 144Filing
- 5 Form 144 notice NAMSNoticeMar 5, 2026 +13 days
Filed to sell 300,000 shares ($9.4M)
Kastelein Johannes Jacob Pieter, Affiliate
10b5-1 plan4.1x usual sizeFiling
- 6 Form 4 sale NAMSUnusualMar 9, 2026 +4 days
Sold 300,000 shares at $30.30 ($9.1M)
Kastelein Johannes Jacob Pieter, Chief Scientific Officer
10b5-1 planSold 81.2% of holdings ($11.2M position)69,302 shares left4.1x usual sizeFollows a Form 144Filing
- 7 Form 144 notice NAMSNoticeAug 24, 2026 +168 days
Filed to sell 125,000 shares ($3.5M)
Kastelein Johannes Jacob Pieter, Affiliate
10b5-1 plan1.7x usual sizeFiling
- 8 Form 4 sale NAMSRoutineAug 24, 2026 same day
Sold 125,000 shares at $26.91 ($3.4M)
Kastelein Johannes Jacob Pieter, Chief Scientific Officer
10b5-1 planSold 64.3% of holdings ($5.2M position)69,302 shares left1.7x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (12)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | Aug 25, 2026 | NAMS | Chief Scientific Officer | Form 4 sale | 125,000 | $3.4M | 64.3% | Routine | SEC |
| Aug 24, 2026 | Aug 24, 2026 | NAMS | Affiliate | Form 144 notice | 125,000 | $3.5M | Notice | SEC | |
| Mar 9, 2026 | Mar 9, 2026 | NAMS | Chief Scientific Officer | Form 4 sale | 300,000 | $9.1M | 81.2% | Unusual | SEC |
| Mar 5, 2026 | Mar 5, 2026 | NAMS | Affiliate | Form 144 notice | 300,000 | $9.4M | Notice | SEC | |
| Feb 20, 2026 | Feb 24, 2026 | NAMS | Chief Scientific Officer | Form 4 sale | 45,481 | $1.6M | 45.9% | Unusual | SEC |
| Feb 20, 2026 | Feb 20, 2026 | NAMS | Officer, Director | Form 144 notice | 45,481 | $1.6M | Notice | SEC | |
| Jan 5, 2026 | Jan 7, 2026 | NAMS | Chief Scientific Officer | Form 4 sale | 6,000 | $200k | 7.5% | Routine | SEC |
| Jan 5, 2026 | Jan 5, 2026 | NAMS | Affiliate | Form 144 notice | 6,000 | $199k | Notice | SEC | |
| Aug 25, 2025 | Aug 25, 2025 | NAMS | Officer, Director | Form 144 notice | 100,000 | $2.5M | Notice | SEC | |
| Aug 22, 2025 | Aug 25, 2025 | NAMS | Chief Scientific Officer | Form 4 sale | 100,000 | $2.5M | 59.1% | Unusual | SEC |
| Mar 26, 2024 | Mar 27, 2024 | NAMS | Chief Scientific Officer | Form 4 sale | 190,476 | $4.1M | 100.0% | Unusual | SEC |
| Mar 26, 2024 | Mar 26, 2024 | NAMS | Officer, Director | Form 144 notice | 190,476 | $4.1M | Notice | SEC |